Active Ingredient History
Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. It was originated by GlycArt Biotechnology AG and developed by Roche. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Anemia (Phase 1/Phase 2)
B-Lymphocytes (Phase 1)
Breast Neoplasms (Phase 1)
Bronchiectasis (Phase 1)
Burkitt Lymphoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 1)
Colorectal Neoplasms (Phase 1/Phase 2)
Cyclin D1 (Phase 2)
Drug Therapy (Phase 2)
Fatigue (Phase 2)
Fever (Phase 2)
Geriatrics (Phase 2)
Glomerulonephritis, Membranous (Phase 2)
Graft vs Host Disease (Phase 2)
Granulomatosis with Polyangiitis (Phase 2)
Hodgkin Disease (Phase 1)
Infusions, Intravenous (Phase 2)
Kidney Diseases (Phase 3)
Kidney Failure, Chronic (Phase 1)
Leukemia (Phase 2)
Leukemia, B-Cell (Phase 1)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Lymphoid (Phase 3)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Prolymphocytic (Phase 1)
Leukemia, Prolymphocytic, B-Cell (Phase 1/Phase 2)
Lupus Erythematosus, Systemic (Phase 3)
Lupus Nephritis (Phase 3)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 3)
Lymphoma, Follicular (Phase 4)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell, Peripheral (Phase 1)
Lymphoproliferative Disorders (Phase 2)
Melanoma (Phase 1)
Microscopic Polyangiitis (Phase 2)
Mycosis Fungoides (Phase 1)
Neoplasms ()
Purpura, Thrombocytopenic, Idiopathic (Phase 2)
Sclerosis (Phase 2)
Splenomegaly (Phase 2)
Sweat (Phase 2)
Therapeutics (Phase 2)
Tissues (Phase 2)
Translocation, Genetic (Phase 2)
Transplantation (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
Weight Loss (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue